ArrePath
Deidre Johns serves as the Head of Chemistry at ArrePath since August 2024, following a role as VP of Chemistry at Rezo Therapeutics. Previously, Deidre was the Director of Medicinal Chemistry at Turning Point Therapeutics and a Principal Scientist in Medicinal Chemistry at Takeda, focusing on research related to gastrointestinal and liver diseases. Deidre's academic career includes positions as Principal Investigator and Assistant Professor at Oregon State University and a Senior Research Scientist at Eli Lilly. Earlier experience includes work at Los Alamos National Laboratory and Air Products & Chemicals. Deidre Johns earned a Ph.D. in Organic Chemistry from the University of Colorado Boulder and completed postdoctoral work funded by the American Cancer Society.
This person is not in any teams
This person is not in any offices
ArrePath
ArrePath was founded upon the mission to discover new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies. We apply world-class science and innovation in imaging and AI / ML technologies to identify and develop novel drugs to address global health issues. Our advanced machine learning (ML) and imaging-based drug discovery platform enables a rapid and efficient identification of new drug classes with desired activity profiles and clinical utility, coupled with a deep understanding of mechanism of action at the outset of the discovery process.